Curia Global is laying off 81 employees as part of its plan to shut down its drug product development and manufacturing facility in Burlington, Massachusetts.
The layoffs were revealed in a Massachusetts Worker Adjustment and Retraining Notification (WARN), which listed the effective dates of the reductions between March 10 and June 1.
The layoffs will begin March 10, although “it is possible that one or more employees will remain employed for a limited time” to help with administrative tasks, according to the WARN filing obtained by Fierce. Final separations for any remaining employees are expected to happen by June 1.
News of the layoffs comes just three months after the facility was named “Manufacturer of the Year” by the Massachusetts Legislative Manufacturing Caucus and honored at a ceremony at Gillette Stadium.
The 35-year-old company, which is based in Albany, New York, and was originally known as Albany Molecular Research Inc., did not respond to a request for comment.
The Burlington facility has been part of Curia’s worldwide network since 2010 when the CDMO acquired Hyaluron. The plant specialized in sterile drug manufacturing, including vials and prefilled syringes used for late-stage clinical trials and commercial products. Upon receiving its recent award, Curia described the facility as being known for its “solvent-based processes, highly viscous products and controlled substances.”
There are 20 facilities under Curia’s umbrella, including commercial manufacturing plants in Albuquerque, New Mexico; Camarillo, California; and Glasgow, U.K. Curia also conducts small-molecule manufacturing at eight sites in Europe, including three each in Italy and Spain. It also has two facilities in India.
In 2024, Curia sold an early-phase development and manufacturing facility in Grafton, Wisconsin, to Swiss CDMO Siegfried. The plant employed more than 80 workers upon its sale.